Drug Search Results
More Filters [+]

Pilocarpine hydrochloride

Alternative Names: pilocarpine hydrochloride, pilocarpine, salagen, vuity, arvn-003, arvn003, isopto carpine, PILOCARPINA, ocusert pilo-20, pilopine hs, ocusert pilo-40
Latest Update: 2024-07-28
Latest Update Note: Clinical Trial Update

Product Description

Pilocarpine Hydrochloride is the hydrochloride salt of a natural alkaloid extracted from plants of the genus Pilocarpus with cholinergic agonist activity. As a cholinergic parasympathomimetic agent, pilocarpine predominantly binds to muscarinic receptors, thereby inducing exocrine gland secretion and stimulating smooth muscle in the bronchi, urinary tract, biliary tract, and intestinal tract.  (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Pilocarpine-hydrochloride)

Mechanisms of Action: AChR Agonist,mAChR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Topical,Ophthalmic

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Cyprus | Denmark | Dominican Republic | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela

Approved Indications: Hypertension | Miosis | Glaucoma | Glaucoma, Angle-Closure | Glaucoma, Open-Angle | Presbyopia

Known Adverse Events: Eye Pain | Headache | Pain Unspecified | Hyperemia

Company: Roxane Laboratories
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pilocarpine hydrochloride

Countries in Clinic: China, United States

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Presbyopia

Phase 2: Dry Eye Disease|Dry Eye Syndromes|Keratoconjunctivitis Sicca|Xerostomia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SYH9042-001

P3

Not yet recruiting

Presbyopia

2025-11-30

VISION-2

P3

Completed

Presbyopia

2022-09-20

38%

VISION-2

P3

Completed

Presbyopia

2022-09-20

38%

ILUT-401-PRES

P2

Completed

Presbyopia

2022-09-06

24%

ILUT-401-DED

P2

Completed

Dry Eye Syndromes|Keratoconjunctivitis Sicca|Dry Eye Disease

2022-07-27

24%

Recent News Events